Orgenesis Inc
NASDAQ:ORGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orgenesis Inc
Total Liabilities
Orgenesis Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orgenesis Inc
NASDAQ:ORGS
|
Total Liabilities
$38.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
Orgenesis Inc
Glance View
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 151 full-time employees. The company went IPO on 2010-07-01. The firm is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The company has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.
See Also
What is Orgenesis Inc's Total Liabilities?
Total Liabilities
38.9m
USD
Based on the financial report for Dec 31, 2024, Orgenesis Inc's Total Liabilities amounts to 38.9m USD.
What is Orgenesis Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
22%
Over the last year, the Total Liabilities growth was 9%. The average annual Total Liabilities growth rates for Orgenesis Inc have been 22% over the past three years , -15% over the past five years , and 22% over the past ten years .
